Lentinan: hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukemia
| Autor: | Jørn Skavland, Emmet McCormack, Øystein Bruserud, Bjørn Tore Gjertsen, Maja Mujic |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
Cancer Research Myeloid Lentinan Medicine (miscellaneous) Pharmacology Cachexia chemistry.chemical_compound Adjuvants Immunologic Rats Inbred BN medicine Idarubicin Animals Nutrition and Dietetics business.industry Myeloid leukemia medicine.disease Blood Cell Count Hematopoiesis Rats Haematopoiesis Leukemia Disease Models Animal Leukemia Myeloid Acute medicine.anatomical_structure Oncology chemistry Immunology Cytarabine Cytokines business medicine.drug |
| Zdroj: | Nutrition and cancer. 62(5) |
| ISSN: | 1532-7914 |
| Popis: | Lentinan, a beta-glucan nutritional supplement isolated from the shitake mushroom (Lentula edodes), is a biological response modifier with immunostimulatory properties. Concomitantly, the role of beta-glucans as chemoimmunotherapeutic in a number of solid cancers has been widely documented. We investigated the effects of nutritional grade lentinan upon BN rats and in a preclinical syngeneic model of acute myeloid leukemia. BN rats supplemented daily with lentinan exhibited weight gains, increased white blood cells, monocytes, and circulating cytotoxic T-cells; and had a reduction in anti-inflammatory cytokines IL-4, IL-10, and additionally IL-6. Lentinan treatment of BN rats with BNML leukemia resulted in improved cage-side health and reduced cachexia in the terminal stage of this aggressive disease. Combination of lentinan with standards of care in acute myeloid leukemia, idarubicin, and cytarabine increased average survival compared with monotherapy and reduced cachexia. These results indicate that nutritional supplementation of cancer patients with lentinan should be further investigated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |